Key result
Targeting ferroptosis emerges as a promising therapeutic strategy across ischemia/reperfusion injury, heart failure, and atherosclerosis.
Answers are grounded in this paper and cite their sources.
Cardiovascular diseases (CVDs) are still a major cause of global mortality and disability, seriously affecting people's lives. Due to the severity and complexity of these diseases, it is important to find new regulatory mechanisms to treat CVDs. Ferroptosis is a new kind of regulatory cell death currently being investigated. Increasing evidence showed that ferroptosis plays an important role in CVDs, such as in ischemia/reperfusion injury, heart failure, cardiomyopathy, and atherosclerosis. Protecting against CVDs by targeting ferroptosis is a promising approach; therefore, in this review, we summarized the latest regulatory mechanism of ferroptosis and the current studies related to each CVD, followed by critical perspectives on the ferroptotic treatment of CVDs and the future direction of this intriguing biology.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2022) conducted a review in Cardiovascular diseases (ischemia/reperfusion injury, heart failure, cardiomyopathy, atherosclerosis). Targeting ferroptosis was evaluated. Ferroptosis plays a key regulatory role in ischemia/reperfusion injury, heart failure, cardiomyopathy, and atherosclerosis, representing a promising therapeutic target for cardiovascular diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: